Last reviewed 2026-05-19 · How we verify

Orifer F®

The Hospital for Sick Children · FDA-approved active Small molecule ✓ Verified May 2026

Orifer F® is a Iron supplement with folic acid Small molecule drug developed by The Hospital for Sick Children. It is currently FDA-approved for Iron deficiency anemia, Iron supplementation in pregnancy or lactation. Also known as: Dietary supplement-prenatal multivitamin.

Orifer F® is an iron supplement that provides ferrous iron for oral absorption to treat or prevent iron deficiency anemia.

Orifer F is a small molecule used in the treatment of pregnancy-related conditions such as morning sickness, nausea, vomiting, and hyperemesis gravidarum. It is also known as Pregvit and has been studied in clinical trials for improving multivitamin supplementation in pregnant women.

At a glance

Generic name	Orifer F®
Also known as	Dietary supplement-prenatal multivitamin
Sponsor	The Hospital for Sick Children
Drug class	Iron supplement with folic acid
Modality	Small molecule
Therapeutic area	Hematology
Phase	FDA-approved

Mechanism of action

Orifer F® contains ferrous iron in a formulation designed for oral bioavailability. The ferrous form is readily absorbed in the gastrointestinal tract and incorporated into hemoglobin and myoglobin, restoring oxygen-carrying capacity in patients with iron deficiency. The 'F' designation typically indicates the presence of folic acid, which supports red blood cell production and addresses concurrent folate deficiency.

Approved indications

Iron deficiency anemia
Iron supplementation in pregnancy or lactation

Common side effects

Gastrointestinal upset (nausea, constipation, abdominal discomfort)
Dark stools
Metallic taste

Key clinical trials

Improving Multivitamin Supplementation to Pregnant Women (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Orifer F® CI brief — competitive landscape report
Orifer F® updates RSS · CI watch RSS
The Hospital for Sick Children portfolio CI

Frequently asked questions about Orifer F®

What is Orifer F®?

Orifer F® is a Iron supplement with folic acid drug developed by The Hospital for Sick Children, indicated for Iron deficiency anemia, Iron supplementation in pregnancy or lactation.

How does Orifer F® work?

Orifer F® is an iron supplement that provides ferrous iron for oral absorption to treat or prevent iron deficiency anemia.

What is Orifer F® used for?

Orifer F® is indicated for Iron deficiency anemia, Iron supplementation in pregnancy or lactation.

Who makes Orifer F®?

Orifer F® is developed and marketed by The Hospital for Sick Children (see full The Hospital for Sick Children pipeline at /company/the-hospital-for-sick-children).

Is Orifer F® also known as anything else?

Orifer F® is also known as Dietary supplement-prenatal multivitamin.

What drug class is Orifer F® in?

Orifer F® belongs to the Iron supplement with folic acid class. See all Iron supplement with folic acid drugs at /class/iron-supplement-with-folic-acid.

What development phase is Orifer F® in?

Orifer F® is FDA-approved (marketed).

What are the side effects of Orifer F®?

Common side effects of Orifer F® include Gastrointestinal upset (nausea, constipation, abdominal discomfort), Dark stools, Metallic taste.

Drug class: All Iron supplement with folic acid drugs
Manufacturer: The Hospital for Sick Children — full pipeline
Therapeutic area: All drugs in Hematology
Indication: Drugs for Iron deficiency anemia
Indication: Drugs for Iron supplementation in pregnancy or lactation
Also known as: Dietary supplement-prenatal multivitamin

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing